Equities research analysts predict that Illumina, Inc. (NASDAQ:ILMN) will report $1.24 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Illumina’s earnings, with the lowest EPS estimate coming in at $1.14 and the highest estimate coming in at $1.34. Illumina posted earnings per share of $1.60 during the same quarter last year, which indicates a negative year over year growth rate of 22.5%. The business is expected to issue its next earnings results on Thursday, April 23rd.
On average, analysts expect that Illumina will report full year earnings of $6.86 per share for the current financial year, with EPS estimates ranging from $6.47 to $7.00. For the next financial year, analysts anticipate that the company will post earnings of $8.04 per share, with EPS estimates ranging from $7.80 to $8.46. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Illumina.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Wednesday, January 29th. The life sciences company reported $1.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.58 by $0.12. Illumina had a return on equity of 22.34% and a net margin of 28.27%. The company had revenue of $953.00 million during the quarter, compared to the consensus estimate of $950.16 million. During the same period last year, the business earned $1.32 EPS. The business’s quarterly revenue was up 9.9% on a year-over-year basis.
In other Illumina news, SVP Oene Mark Van sold 625 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $300.24, for a total value of $187,650.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Susan H. Tousi sold 200 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $325.00, for a total value of $65,000.00. Following the completion of the sale, the senior vice president now directly owns 38,465 shares in the company, valued at approximately $12,501,125. The disclosure for this sale can be found here. Insiders sold a total of 4,197 shares of company stock worth $1,345,987 in the last ninety days. Insiders own 0.38% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Princeton Global Asset Management LLC acquired a new stake in Illumina in the 4th quarter valued at approximately $25,000. Credit Agricole S A acquired a new stake in Illumina in the 4th quarter valued at approximately $28,000. Massey Quick Simon & CO. LLC grew its holdings in Illumina by 3,100.0% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 96 shares of the life sciences company’s stock valued at $29,000 after buying an additional 93 shares during the last quarter. Savior LLC acquired a new stake in Illumina in the 4th quarter valued at approximately $31,000. Finally, Trust Co. of Vermont grew its holdings in Illumina by 296.8% in the 3rd quarter. Trust Co. of Vermont now owns 123 shares of the life sciences company’s stock valued at $37,000 after buying an additional 92 shares during the last quarter. 91.80% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ ILMN traded up $7.54 during mid-day trading on Friday, reaching $298.92. 1,494,400 shares of the company traded hands, compared to its average volume of 1,355,955. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.15 and a current ratio of 6.69. The stock has a market cap of $43.28 billion, a PE ratio of 44.28, a price-to-earnings-growth ratio of 2.78 and a beta of 1.12. The company’s fifty day moving average is $316.61 and its two-hundred day moving average is $305.87. Illumina has a fifty-two week low of $263.30 and a fifty-two week high of $380.76.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Quantitative Easing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.